Research memoAbbott Laboratories (ABT) · NYSEMemo of October 13, 2026

Abbott dividend: payment and cash coverage

Abbott's dividend base path rises from $2.64 per share to $3.00. Abbott generated $7,395 million of free cash flow in 2025 before dividends, showing cash coverage for the payout.

2.35
Dividend paid per share, 2025
2.5%
Dividend yield
3.8%
Real free cash flow yield
4.2%
Free cash flow yield
Read the full Abbott memoYour first report is free · no card
Every number traced to Abbott's filings8 chapters · 17,130 words261 sources cited

How much does Abbott pay in dividends over time?

The dividend base path rises from $2.64 per share to $3.00. The bear case holds at $2.52, the current annualized rate, while the bull case reaches $3.20. The base reflects Abbott's 54-year record of increases and $7,395 million of 2025 free cash flow, but the bear freeze recognizes that net debt reached about $27,005 million after Exact.

Dividend per share against free cash flow per share (US$ per share)1.794.4820211.884.0420222.032.5220232.193.2520242.353.852025Dividends paid, per shareReal free cash flow per share
ResultsUS$ millions
20252024202320222021
EPS, diluted3.727.643.263.913.94
Dividend per share2.402.242.081.921.82

Does Abbott's cash cover its dividend?

Operating activities produced $9,566 million of cash in 2025. Capital spending used $2,171 million, leaving $7,395 million of free cash flow. Free cash flow is cash left after operating needs and property investment, before dividends, acquisitions and debt repayment. It improved from $5,059 million in 2023 but remained below $8,648 million in 2021.

The 2024 cash-flow reconciliation included an $8,028 million deduction labelled income taxes, but Abbott separately reported $1,723 million of cash taxes paid. The larger deduction mainly reconciled the noncash tax benefit, rather than showing ordinary cash taxes or inventory purchases. Stock compensation is also noncash in the cash-flow statement, but it dilutes shareholders or requires repurchases. Deducting $664 million of stock pay gives analytical “real free cash flow” of $6,731 million.

Follow the money: where the free cash flow wentUS$ millions
20252024202320222021
Free cash flow7,3956,3515,0597,8048,648
− Dividends paid4,1163,8363,5563,3093,202
− Share buybacks8931,2951,2273,7952,299
Paid to shareholders5,0095,1314,7837,1045,501
Paid out, % of free cash flow67.7%80.8%94.5%91.0%63.6%

What could change Abbott's dividend?

The view moves toward the bear if Nutrition volume remains weak, legal cash costs persist, or sensor reliability damages adoption. Exact is the key dated test: continued dilution through 2027 supports the base only if synergies and contribution appear in 2028 as expected. Faster debt repayment alongside continued buybacks would support the bull; restrained repurchases and declining cash conversion would support the bear.

The forecast's tablebase case, then bear / bull in brackets; USD millions, per share in USD, unless shown
October 2027October 2028October 2029
Earnings7,540 (6,464 / 8,025)8,310 (6,760 / 9,396)9,145 (7,062 / 10,710)
Shares (millions)1,724 (1,731 / 1,720)1,718 (1,732 / 1,711)1,712 (1,732 / 1,703)
Dividends per share2.64 (2.52 / 2.72)2.80 (2.52 / 2.96)3.00 (2.52 / 3.20)
Price to earnings26.00 (22.00 / 30.00)25.00 (20.00 / 31.00)24.00 (18.00 / 32.00)

What is Abbott's dividend yield today?

Free cash flow measures operating cash after spending on long-lived assets such as factories and equipment. Abbott’s 4.2% free-cash-flow yield means the business generated about $4.20 for each $100 of equity value; its stricter “real” yield is 3.8%. Neither is a promised payment. Cash can fund dividends, debt repayment or investment. A FreeStyle Libre 3 Plus sensor lasts up to 15 days, creating repeat demand, but coverage, competition and pricing decide how much becomes durable cash.

From the full memo · 1. The business

Abbott Laboratories is a healthcare company that sells devices, diagnostic tests, nutrition and established medicines. Its business becomes clear when we follow a product from the reason someone needs it to the way a sale is paid for, delivered and repeated.

Continue reading, free
Your first report is free · no card

Where these numbers come from

More on Abbott

Abbott stock forecastAbbott earnings

Its rivals

Medtronic (MDT)Danaher (DHR)Thermo Fisher Scientific (TMO)BD (BDX)

Browse

All stocksS&P 500 companiesCompanies A
The full Abbott memoYour first report is free
Read it